Star Combo Pharma Ltd (S66) — Capital Reinvestment Ratio
Star Combo Pharma Ltd (S66) has a Capital Reinvestment Ratio of 0.51x as of December 2025, meaning it reinvests 1% of its operating cash flow (AU$575.23K) in capital expenditures (AU$295.53K). Check S66 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Star Combo Pharma Ltd Capital Reinvestment Ratio (2016–2025)
This chart tracks Star Combo Pharma Ltd's Capital Reinvestment Ratio across 6 annual periods. For the full cash flow conversion analysis, see S66 cash generation efficiency.
Annual Capital Reinvestment Ratio for Star Combo Pharma Ltd (2016–2025)
Year-by-year Capital Reinvestment Ratio for Star Combo Pharma Ltd from 2016 to 2025. See Star Combo Pharma Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (AUD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.03x | AU$11.94 Million | AU$393.72K | ▼ -97.7% |
| 2023 | 1.45x | AU$1.88 Million | AU$2.73 Million | ▼ -98.3% |
| 2022 | 83.74x | AU$87.11K | AU$7.29 Million | ▲ +282.5% |
| 2021 | 21.89x | AU$331.53K | AU$7.26 Million | ▲ +7714.6% |
| 2017 | 0.28x | AU$932.20K | AU$261.13K | ▼ -68.3% |
| 2016 | 0.88x | AU$1.30 Million | AU$1.15 Million | — |